SCHEMBL664758

SCHEMBL664758

CC1(C)OB(c2cnn(C3CCN(S(C)(=O)=O)CC3)c2)OC1(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 6/20 0.41
CDK2 P24941 6/20 0.41
CDK1 P06493 4/20 0.41
CCNB1 P14635 4/20 0.41
JAK1 P23458 2/20 0.41
JAK3 P52333 1/20 0.41
CDK4 P11802 2/20 0.40
CCND1 P24385 2/20 0.40
CCND3 P30281 2/20 0.40
CDK6 Q00534 2/20 0.40
FFAR1 O14842 1/20 0.40
MET P08581 3/20 0.38
MAP4K1 Q92918 1/20 0.38
LRRK2 Q5S007 4/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
FGFR1 P11362 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR4 P22455 1/20 0.35
FGFR3 P22607 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21794911 0.89 FFAR1 (0.39) CCNE1CDK2CDK1CCNB1JAK1
SCHEMBL25514242 0.87 FFAR1 (0.38) CCNE1CDK2CDK1CCNB1JAK1
SCHEMBL2517121 0.84 FFAR1 (0.47) JAK1JAK3FFAR1
SCHEMBL2572488 0.84 FFAR1 (0.47) JAK1JAK3FFAR1LRRK2
SCHEMBL1987497 0.84 FFAR1 (0.49) JAK1JAK3FFAR1LRRK2
SCHEMBL657486 0.83 FFAR1 (0.44) FFAR1MET
SCHEMBL2749177 0.83 FFAR1 (0.46) CCNE1CDK2CDK1CCNB1JAK1
SCHEMBL17801242 0.83 FFAR1 (0.46) CCNE1CDK2CDK1CCNB1JAK1
SCHEMBL659001 0.83 FFAR1 (0.39) CCNE1CDK2CDK1CCNB1JAK1
SCHEMBL28649940 0.82 FFAR1 (0.46) FFAR1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378096-B2 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-19 US claimed
US-20230339936-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY CYTOSINLAB THERAPEUTICS CO., LTD. (CN) 2023-10-26 US disclosed
US-20230339936-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY CYTOSINLAB THERAPEUTICS CO., LTD. (CN) 2023-10-26 US disclosed
EP-4186901-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY Cytosinlab Therapeutics Co., Ltd. (CN) 2023-05-31 EP disclosed
US-10052330-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2018-08-21 US disclosed
EP-2718293-B1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LTD (CN) 2017-10-25 EP disclosed
EP-2718293-B1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LTD (CN) 2017-10-25 EP disclosed
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED 2016-11-10 US disclosed
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED 2016-11-10 US disclosed
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED 2016-11-10 US disclosed
US-9434726-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2016-09-06 US disclosed
US-9434726-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2016-09-06 US disclosed
US-20140121200-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-05-01 US disclosed
US-20140121200-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-05-01 US disclosed
US-20140121200-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-05-01 US disclosed
EP-2718293-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS Hutchison Medipharma Limited (CN) 2014-04-16 EP disclosed
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 US disclosed
WO-2012167733-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2012-12-13 WO disclosed
WO-2012167733-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2012-12-13 WO disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS SYK, BTK, LYN CCNE1 1373/4885CDK2 492/4885CDK1 584/4885
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES MAP3K5, STK17A, MAPKAPK5 CCNE1 1323/4885CDK2 290/4885CDK1 67/4885
US-10052330-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors SYK, BTK, TYRO3 CCNE1 1842/4885CDK2 506/4885CDK1 590/4885
US-20230339936-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY FLT3, ERBB2, ABL1 CCNE1 976/4885CDK2 131/4885CDK1 208/4885
US-20140121200-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS SYK, BTK, LYN CCNE1 1387/4885CDK2 546/4885CDK1 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.